Verified peer comparison
MRK vs LLY
Merck & Co., Inc. compared with Eli Lilly and Company. This page compares both source-verified company profiles and does not introduce an unverified price target.
MRK
Merck & Co., Inc.
$189.43
- Open
- --
- High
- --
- Low
- --
- Market Cap
- --
LLY
Eli Lilly and Company
$782.10
- Open
- --
- High
- --
- Low
- --
- Market Cap
- --
Company-specific comparison
Business exposure
MRK: Pharmaceuticals
LLY: Pharmaceuticals
Upside lens
MRK: Continued oncology demand and new indications can sustain growth while Merck expands the franchise beyond its established uses. Increasing contributions from newer medicines across cardiometabolic, respiratory, and HIV markets can diversify growth beyond the largest established products. A robust period of Phase 3 readouts and regulatory milestones could validate Merck's efforts to build a broader set of future growth drivers.
LLY: obesity drug adoption and pipeline expansion
Risk lens
MRK: Merck remains highly dependent on Keytruda, making future patent expiry, competition, and the pace of portfolio diversification material risks. Declines in vaccines, including demand pressure affecting Gardasil, can offset gains in oncology and newer launches. Large acquisition-related charges and continuing development investment can create earnings volatility before acquired pipeline assets generate returns.
LLY: supply constraints and valuation expectations
Verified sources
Merck Announces First-Quarter 2026 Financial ResultsMerck & Co., Inc. · earningsVerified
Merck Investor RelationsMerck & Co., Inc. · companyVerified
Fetched: 7/12/2026, 12:00:00 AM UTC
Open original sourceMerck Form 10-Q for the Quarter Ended March 31, 2026U.S. Securities and Exchange Commission · filingVerified
Fetched: 7/12/2026, 12:00:00 AM UTC
Open original sourceLilly Reports First-Quarter 2026 Financial ResultsEli Lilly and Company · earningsVerified
Eli Lilly Investor RelationsEli Lilly and Company · companyVerified
Fetched: 7/11/2026, 12:00:00 AM UTC
Open original sourceForm 10-Q for the Quarter Ended March 31, 2026Eli Lilly and Company · filingVerified
LLY editorial research profileAlphaVue Research · editorialVerified
Fetched: 7/11/2026, 12:00:00 AM UTC